Background: Glycogen synthase kinase-3 (GSK3) and the O subfamily of forkhead/winged helix transcription factors (FOXO) have pro-tumor or anti-tumor roles in human cancers. Results: GSK3 up-regulates type I insulin-like growth factor receptor (IGF-IR) expression and IGF-I-induced hepatoma cell proliferation through FOXO1/3/4. Conclusion: GSK3 and FOXO promote hepatoma cell proliferation through IGF-IR. Significance: These findings inform how GSK3 and FOXO promote cell proliferation. Glycogen synthase kinase-3 (GSK3) has either tumor-suppressive roles or pro-tumor roles in different types of human tumors. A number of GSK3 targets in diverse signaling pathways have been uncovered, such as tuberous sclerosis complex subunit 2 and ␤-catenin. The O subfamily of forkhead/winged helix transcription factors (FOXO) is known as tumor suppressors that induce apoptosis. In this study, we find that FOXO binds to type I insulin-like growth factor receptor (IGF-IR) promoter and stimulates its transcription. GSK3 positively regulates the transactivation activity of FOXO and stimulates IGF-IR expression. Although kinase-dead GSK3␤ cannot up-regulate IGF-IR, the constitutively active GSK3␤ induces IGF-IR expression in a FOXO-dependent manner. Serum starvation or Akt inhibition leads to an increase in IGF-IR expression, which could be blunted by GSK3 inhibition. GSK3␤ knockdown or GSK3 inhibitor suppresses IGF-I-induced IGF-IR, Akt, and ERK1/2 phosphorylation. Moreover, knockdown of GSK3␤ or FOXO1/3/4 leads to a decrease in cellular proliferation and abrogates IGF-I-induced hepatoma cell proliferation. These results suggest that GSK3 and FOXO may positively regulate IGF-I signaling and hepatoma cell proliferation.
implicated in the regulation of glucose transport. Activation of GSK3 leads to a decrease in glucose transporter 1 expression and glucose uptake (4) . Whereas phosphorylation at tyrosine 216 in GSK3␤ or tyrosine 279 in GSK3␣ enhances the kinase activity of GSK3, phosphorylation of serine 9 in GSK3␤ or serine 21 in GSK3␣ significantly decreases its enzymatic activity (5) . The best characterized upstream kinase that inactivates GSK3␤ through phosphorylation of its N terminus at Ser-9 is Akt/PKB (6) . In addition, protein kinase A (PKA), PKC, p90 ribosomal S6 kinase, and p70 ribosomal S6 kinase (p70S6K) are known to phosphorylate Ser-9 of GSK3␤ in a context-dependent manner (7) . p38 mitogen-activated protein kinase (MAPK) also inactivates GSK3␤ in the brain and thymocytes by direct phosphorylation at its C-terminal Ser-389 residue (8) .
Since the discovery of GSK3, an increasing number of GSK3 targets in diverse signaling pathways have been uncovered, such as tuberous sclerosis complex subunit 2 (TSC2) and ␤-catenin (9) . Phosphorylation by GSK3 may either positively or negatively regulates its downstream substrates. GSK3 has been found to regulate the proteolysis of an increasing number of proteins. For example, casein kinase I phosphorylation of ␤-catenin primes it for subsequent GSK3␤ phosphorylation at multiple sites at the N terminus, leading to the recognition by ␤-transducin repeat containing E3 ubiquitin protein ligase and rapid degradation by the 26 S proteasome (10) . Also, phosphorylation by GSK3 induces both activation and degradation of MafA, SRC-3, and BCL-3 (11) (12) (13) (14) .
Previous studies indicate that GSK3␤ is a double-edged sword in tumorigenesis. Both GSK3␤ inhibition and activation may drive tumor progression, depending on the cell type. Although GSK3␤ promotes tumorigenesis in some cancer types such as pancreatic cancer, ovarian cancer, and leukemia, it inhibits tumor growth in breast cancer and skin cancer (15) (16) (17) (18) (19) . The inactivation of GSK3␤ has been detected in some cancer types, such as skin, breast, lung cancer, and melanoma, but is absent in gastrointestinal cancer, hepatic cancer, and pancreatic cancer (20) . The mechanisms underlying the pleiotrophic effects of GSK3␤ may be attributable to its central role in diverse signaling pathways such as Wnt, Notch, Hedgehog, and nuclear factor-B (NF-B) pathways (21) . Whereas GSK3 targets ␤-catenin, a key mediator in the Wnt pathway, for proteasomal degradation, thereby antagonizing Wnt signaling, it targets IB, a repressor of NF-B, for degradation, thereby promoting NF-B activation.
Besides GSK3␤, the O subfamily of Forkhead/winged helix transcription factors (FOXO) is another downstream substrate of Akt, a key signaling node in multiple signal transduction pathways, including insulin signaling, insulin-like growth factor (IGF) signaling, and epidermal growth factor signaling. FOXO proteins are phylogenetically conserved and regulate key physiological functions, including cell proliferation, cell differentiation, and survival (22) . Similar to GSK3, phosphorylation of FOXO by Akt leads to inactivation of FOXO. FOXOs activate transcription of the cell cycle inhibitors p27 Kip1 and p21 Cip1/WAF1 , although they repress transcription of the cell cycle activators cyclin D1 and cyclin D2 (23) . FOXO also activates the cell cycle inhibitor cyclin G 2 (24) . Moreover, insulin and IGF-I have been reported to down-regulate the expression of cyclin G 2 as part of their mitogenic effect (25) . Hence, FOXOs are considered as tumor suppressors. However, signaling downstream of FOXO is both cell type-specific and tissuespecific. FOXOs are lineage-restricted redundant tumor suppressors (26) . Although many studies indicate that FOXOs are bona fide tumor suppressors, recent studies demonstrate that they have roles in promoting tumorigenesis and drug resistance. Depletion of FOXO3 reduced G 1 /S transition and cell proliferation in MCF7 breast cancer cells and H1299 lung cancer cells (27) . Elevated FOXO3 expression is associated with poor prognosis in patients with acute myeloid leukemia exhibiting normal cytogenetics, and genetic ablation of FOXO3 reduces disease burden in a murine model of chronic myeloid leukemia (28, 29) . Another recent study has revealed that FOXO inhibition triggers myeloid cell maturation and acute myeloid leukemia cell death (30) . FOXOs promote survival of hematopoietic cells after DNA damage (31) . In addition, FOXOs up-regulate BCL-10 and activate NF-B, thereby promoting survival of tumor cells under serum starvation (32) . Interestingly, GSK3␤ positively regulates FOXO1 activity through direct binding to FOXO1 (33) . Insulin and IGF signaling can induce Akt-mediated GSK3␤ and FOXO phosphorylation, resulting in the inactivation of GSK3␤ and FOXO.
Even though GSK3 is a well known downstream target of IGF-IR, 2 it remains unclear whether GSK3␤ controls upstream elements governing IGF-IR signaling. Here, we report that GSK3 positively regulates IGF-IR expression. These effects are mediated, at least in part, by activation of FOXO transcription factors that directly bind to the IGF-IR promoter. Inhibition of GSK3 leads to a decrease in IGF-I-induced Akt and ERK1/2 phosphorylation and cellular proliferation. Together, these findings provide a mechanism whereby GSK3␤ enhances IGF-I signaling in hepatoma cells.
EXPERIMENTAL PROCEDURES
Reagents-LiCl was purchased from Sigma. IGF-I was purchased from PeproTech Inc. (Rocky Hill, NJ) and prepared by reconstituting in deionized water to the appropriate concentration and stored at Ϫ20°C. The anti-IGF-IR, anti-FOXO1, anti-FOXO3, anti-FOXO4, anti-Akt, anti-ERK1/2, anti-HA, antiphosphorylated IGF-IR (Tyr-1135), anti-phosphorylated Akt (Ser-473), and anti-phosphorylated ERK1/2 antibodies were purchased from Cell Signaling Technology (Beverly, MA). Another FOXO1 antibody for chromatin immunoprecipitation was from Abcam Ltd. (Shatin, N.T., Hong Kong). Anti-GSK3 antibody was purchased from Signalway Antibody LLc (Baltimore, MD). Anti-phosphorylated GSK3␤ (Ser-9) was purchased from Eptomics (Burlingame, CA). Anti-actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Culture-Hepatoma cancer cell lines HepG2 and SMMC-7721 were maintained in Dulbecco's minimal essential medium (DMEM) containing 10% newborn calf serum and incubated at 37°C in a humidified atmosphere of 5% CO 2 . Culture medium was changed every 2 days.
RNA Interference-The two target sequences for GSK3␤ knockdown are as follows: 1, GATCTGTCTTGAAGGAGAA; Western Blotting-Cells were lysed with cold RIPA lysis buffer containing protease inhibitors for 30 min. 30 g of protein was loaded into Tris-HCl-polyacrylamide gels and transferred to PVDF membrane. The membrane was blocked with 5% BSA in TBST, followed by incubating with primary antibody overnight at 4°C. After rinsing the membrane in TBST three to four times, the membrane was incubated with appropriate HRP-labeled secondary antibody for 1 h at room temperature. The membrane was detected with chemifluorescent reagent.
Quantitative Reverse Transcription-PCR-Total RNAs were extracted from cultured cells using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. First strand cDNAs were synthesized using the Moloney murine leukemia virus reverse transcriptase and oligo(dT) primers. GSK3␤ and IGF-IR were amplified by real time PCR using the SYBR Select Master Mix (Invitrogen), and the total volume was 20 l. ␤-Actin was also amplified as a reference gene. The primer sequences for human GSK3␤ were 5Ј-CTCCTCATGCTCG-GATTCA-3Ј (forward) and 5Ј-TGCAGAAGCAGCATTAT-TGG-3Ј (reverse). The primer sequences for human IGF-IR were 5Ј-AATCGCATCATCATAACCTG-3Ј (forward) and 5Ј-CATCCTGCCCATCATACTC-3Ј (reverse). Relative quantification with the comparative threshold cycle (Ct) was done using the Ct method. The amount of GSK3␤ or IGF-IR gene normalized to the endogenous reference gene (␤-actin) is given by 2Ϫ ⌬Ct, where ⌬Ct is Ct (GSK3␤ or IGF-IR) ϪCt (␤-actin).
Chromatin Immunoprecipitation (CHIP) Assay-ChIP assays were performed with the chromatin immunoprecipitation system according to the manufacturer's instructions (Millipore Corp., Billerica, MA). Briefly, cells were fixed with formaldehyde for 10 min at room temperature. After washing twice with 1ϫ cold PBS containing proteinase inhibitor mixture II, the cells were scraped and lysed with cell lysis buffer and nuclear lysis buffer, and then the DNA was broken into pieces 200 -1,000 bp in length by sonication. Soluble chromatin was co-immunoprecipitated with antibody against FOXO1 or IgG at 4°C overnight. The de-cross-linked DNA samples were subjected to PCR. A, HepG2 and SMMC-7721 cells were treated with or without 10 mM LiCl for indicated periods, followed by Western blot analysis of IGF-IR expression. B, HepG2 and SMMC-7721 cells were transfected with siCtrl, siGSK3␤, or siGSK3␤#2 for 48 h, followed by Western blot analysis of GSK3␤ and IGF-IR expression. C, HepG2 and SMMC-7721 cells were transfected with siCtrl, siGSK3␣, or siGSK3␤ for 48 h, followed by Western blot analysis of GSK3 and IGF-IR expression. D, HepG2 cells were transfected with or without HA-tagged phosphomimetic GSK3␤ (K85A) or phosphodeficient GSK3␤ (S9A) mutants, followed by Western blot analysis of IGF-IR and HA. E, HepG2 and SMMC-7721 cells were treated with or without 10 mM LiCl for 24 h, followed by quantitative RT-PCR analysis of IGF-IR expression. The relative levels of IGF-IR transcription were plotted. The relative levels of IGF-IR transcription were plotted. Values represent means Ϯ S.D. *, p Ͻ 0.01. F, HepG2 and SMMC-7721 cells were transfected with siCtrl or siGSK3␤ for 24 h, followed by quantitative RT-PCR analysis of IGF-IR expression. The relative levels of IGF-IR transcription were plotted. Values represent means Ϯ S.D. *, p Ͻ 0.001.
Luciferase Assay-HepG2 or SMMC-7721 cells were seeded in six-well plates. After treatment with lithium chloride (LiCl) or transfection with siRNA or GSK3 plasmids, the cells were transfected with a total of 320 ng of FOXO-responsive luciferase construct (Addgene Inc., Cambridge, MA) per well mixed with the Lipofectamine reagent (Invitrogen). Twenty four hours after transfection, the cells were harvested with 1ϫ reporter lysis buffer (Promega BioSciences, San Luis Obispo, CA). Luciferase activities were measured using the Promega luciferase assay kit.
Cell-light TM EdU Assay-Cells were seeded in 96-well plates at 5000 cells per well. Twenty four hours later, the cells were treated with or without LiCl (5 mM) or siRNA, followed by treating with or without 5 nM IGF-I. After 24 h, the cells were incubated with 50 M EdU medium for 2 h. Next, the cells were fixed with 4% paraformaldehyde for 30 min and incubated with 2 mg/ml glycine for 10 min. Following permeabilization in 0.5% Triton X-100 for 10 min, the cells were incubated in Apollo 567 working solution for 30 min at room temperature. The cells were washed with PBS and then incubated with 1ϫ Hoechst 33342 for 30 min at room temperature. After washing the cells with PBS three times, the cells were observed under fluorescence microscope.
RESULTS
GSK3 Up-regulates the Expression of IGF-IR-To determine whether GSK3 regulates IGF-IR expression, we treated hepatoma cells HepG2 with LiCl, a GSK3 inhibitor, and then detected IGF-IR levels by Western blotting. Treatment of HepG2 with LiCl led to a decrease in IGF-IR expression ( Fig.  1A) . Similar results were detected in another hepatoma cell line, SMMC-7721 ( Fig. 1A ). In addition, transfection of siRNA against GSK3␤ (siGSK3␤) into both HepG2 and SMMC-7721 cells resulted in decreased IGF-IR levels (Fig. 1B) . Similar results were detected in HepG2 and SMMC-7721 cells transfected with another siRNA against GSK3␤ (siGSK3␤#2) (Fig.  1B) . Moreover, GSK3␣ knockdown resulted in decreased IGF-IR expression to a much lesser extent than GSK3␤ depletion ( Fig. 1C ). Therefore, the next studies focus on GSK3␤. Consistent with above-mentioned findings, overexpression of the constitutively active GSK3␤ (K85A) mutant in hepatoma cells led to an increase in IGF-IR expression, although overexpression of the kinase-dead GSK3␤ (S9A) mutant did not affect IGF-IR expression ( Fig. 1D ). To determine whether GSK3␤ regulates IGF-IR expression at the transcription level, we treated hepatoma cells with LiCl and then detected IGF-IR mRNA levels by quantitative RT-PCR. Treatment of hepatoma cells with LiCl led to a decrease in IGF-IR transcription (Fig.  1E ). GSK3␤ knockdown also reduced IGF-IR transcription (Fig.  1F ). Collectively, these data demonstrate that GSK3␤ positively regulates IGF-IR expression.
FOXO1/3/4 Mediate the Induction of IGF-IR Expression by GSK3␤-Although IGF-IR is overexpressed in a variety of tumor cells, little is known how IGF-IR expression is regulated. Bioinformatic analysis of the IGF-IR promoter indicates that there are two potential FOXO-binding sites (site 1, Ϫ1460 TTGTTTTC Ϫ1453 ; site 2, Ϫ981 TTGTTTAC Ϫ974 ) within the promoter of IGF-IR (34) . Previous study also demonstrated that knockdown of FOXO, especially FOXO3, abrogated Akt inhibitor-induced IGF-IR expression in breast cancer cells (35) . However, it remains unknown whether FOXO directly binds to IGF-IR promoter. To determine whether FOXO directly binds to these potential sites, we took advantage of CHIP analysis. We designed two pairs of primers to amplify DNA sequences spanning two potential FOXO-binding sites and one pair of primer to amplify an irrelevant sequence. The chromosome DNA immunoprecipitated by anti-FOXO1 antibody, and IgG was subjected to PCR with three pairs of primers indicated in Fig. 2A . The results demonstrated that FOXO1 binds to the site more close to the transcription start site ( Ϫ981 TTGTTTAC Ϫ973 ) ( Fig. 2A) .
To determine whether FOXO regulates IGF-IR expression in hepatoma cells, we transfected HepG2 and SMMC-7721 cells with siRNA to FOXO1, FOXO3, or FOXO4, followed by Western blot analysis of IGF-IR expression. FOXO1, FOXO3, or FOXO4 knockdown led to a decrease in IGF-IR expression in both HepG2 and SMMC-7721 cells (Fig. 2, B and C) . These data demonstrate that FOXO1, FOXO3, and FOXO4 activate IGF-IR expression.
To ensure that GSK3 regulates FOXO activity in hepatoma cells, we transfected FOXO-luc into HepG2 and SMMC-7721 cells, followed by treatment with LiCl and detection of luciferase activity. LiCl significantly inhibited the transactivation activity of FOXO in both HepG2 and SMMC-7721 cells (Fig.  3A) . In addition, GSK3␤ knockdown resulted in a decrease in the transactivation activity of FOXO (Fig. 3B) . A similar effect was detected in HepG2 and SMMC-7721 cells transfected with siGSK3␤#2 ( Fig. 3C ). Consistent with above-mentioned findings, overexpression of HA-tagged constitutively active GSK3␤ in SMMC-7721 cells led to an increase in the transactivation activity of FOXO, although overexpression of HA-tagged kinase-dead GSK3␤ did not affect the transactivation activity of FOXO (Fig. 3D ). These data demonstrate that GSK3␤ positivity regulate FOXO activity in hepatoma cells.
To determine whether FOXO mediated the effect of GSK3␤ on IGF-IR expression, we transfected constitutively active GSK3␤ into SMMC-7721 cells, followed by transfection with siRNA to FOXO1/3/4 or control siRNA and Western blotting analysis of IGF-IR expression. Overexpression of active GSK3␤ increased IGF-IR expression. FOXO1/3/4 knockdown abrogated the induction of IGF-IR expression by active GSK3␤ (Fig. 3E ). These data demonstrate that GSK3␤ stimulates IGF-IR expression through a FOXO-dependent mechanism.
GSK3␤ and FOXO Mediate Serum Starvation-induced IGF-IR Expression-Because serum starvation could lead to the derepression of GSK3␤, we detected the effects of serum starvation on IGF-IR expression. Upon serum starvation, a decrease in GSK3␤ phosphorylation and an increase in IGF-IR expression were detected in both HepG2 and SEPTEMBER 5, 2014 • VOLUME 289 • NUMBER 36
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SMMC-7721 cells (Fig. 4A ). To determine whether serum starvation leads to changes in IGF-IR transcription, we detected levels of IGF-IR mRNA in serum-starved cells by real time RT-PCR. Serum starvation led to increased IGF-IR transcription in both HepG2 and SMMC-7721 cells (Fig. 4B) . To determine whether GSK3␤ contributes to increased IGF-IR expression in response to serum starvation, HepG2 and SMMC-7721 cells were treated with or without LiCl, followed by serum starvation. Treatment of HepG2 and SMMC-7721 cells with LiCl abrogated the induction of IGF-IR expression by serum starvation (Fig. 4C ). GSK3␤ knockdown also abrogated the induction of IGF-IR expression by serum starvation (Fig. 4D) .
Next, we detected the effect of serum starvation on the transactivation activity of FOXO. Serum starvation resulted in a significant increase in the transactivation activity of FOXO in both HepG2 and SMMC-7721 cells (Fig. 4E) . Treatment with LiCl inhibited the increase in the transactivation activity of FOXO (Fig. 4E ). GSK3␤ knockdown also blunted the stimulation of FOXO activity by serum starvation (Fig. 4F) . Moreover, FOXO1/3/4 knockdown abrogated the induction of IGF-IR expression by serum starvation (Fig. 4G) . These data demonstrate that the GSK3␤-FOXO axis contributes to the induction of IGF-IR expression by serum starvation.
Akt can phosphorylate and inactivate both GSK3 and FOXO. We found that treatment of hepatoma cells with Akt inhibitor resulted in an increase in IGF-IR expression (Fig. 5A) . Treatment of hepatoma cells with LiCl abrogated the increase in IGF-IR expression in response to Akt inhibition (Fig. 5B) .
GSK3␤ Positively Regulates IGF-I Signaling-The abovementioned data demonstrate that GSK3␤ positively regulates IGF-IR expression. To determine the effects of GSK3␤ on IGF-I-induced phosphorylation of IGF-IR and its downstream effectors, including ERK1/2 and Akt, HepG2 cells were pretreated with or without LiCl, followed by treating with or without IGF-I. Cell lysates were harvested and subjected to Western blot analysis of the phosphorylation of IGF-IR, ERK1/2, and Akt. The results demonstrated that LiCl inhibited IGF-IR expression and IGF-I-induced phosphorylation of IGF-IR, ERK1/2, and Akt (Fig. 6A) . Similar results were detected in SMMC-7721 cells (Fig. 6A ).
In addition, HepG2 and SMMC-7721 cells were transfected with or without siRNA against GSK3␤, followed by treating with or without IGF-I. Cell lysates were harvested and subjected to Western blot analysis of the phosphorylation of IGF-IR, ERK1/2, and Akt. GSK3␤ knockdown led to a decrease in IGF-I-induced phosphorylation of IGF-IR, ERK1/2, and Akt in both cell lines (Fig. 6B) . Similar effects were detected in HepG2 and SMMC-7721 cells transfected with siGSK3␤#2 ( Fig. 6C) . Collectively, these data demonstrate that GSK3␤ positively regulates both IGF-IR expression and IGF-I signaling.
GSK3␤ and FOXO1/3/4 Positively Regulate IGF-I-induced Hepatoma Cell Proliferation-IGF-I is a mitogenic growth factor. To determine whether GSK3␤ regulates IGF-I-induced hepatoma cell proliferation, HepG2 cells were treated with or without LiCl and IGF-I, followed by detection of cellular proliferation by EdU labeling. Treatment with LiCl inhibited HepG2 cell proliferation and blunted IGF-I-induced cellular proliferation (Fig. 7, A and B) . Similarly, GSK3␤ knockdown blunted IGF-I-induced cellular proliferation (Fig. 7, C and D) .
Next, we investigated the effects of FOXO knockdown on IGF-I-induced hepatoma cell proliferation. Although IGF-I significantly stimulated HepG2 cell proliferation, knockdown of FOXO1/3/4 inhibited HepG2 cell proliferation and blunted IGF-I-induced cellular proliferation (Fig. 8) . These data indicate that FOXO1/3/4 promote IGF-I-induced hepatoma cell proliferation.
DISCUSSION
Previous studies indicate that IGF-IR is required for the transforming ability of several oncogenes such as simian virus 40 large tumor antigen (36) . In humans, IGF-IR and insulin receptor are widely expressed in normal tissues and frequently overexpressed in tumor cells (37, 38) . Active Src has been shown to up-regulate IGF-IR expression in pancreatic cancer cells (39) . Whereas Akt is identified as a downstream target of Src that positively regulates IGF-IR expression, hyperactive Akt reportedly down-regulates IGF-IR at the transcription level (40, 41) . In both cases, the downstream effectors of Akt signaling that mediate the regulation of IGF-IR have not been identified. Among transcription factors, Sp1, cAMP-response elementbinding protein, and mutant p53 have been shown to up-regulate IGF-IR expression, whereas wild-type p53 and the Wilms tumor suppressor gene WT1 negatively regulate IGF-IR expression (42) (43) (44) (45) . Mechanistically, mutant p53 interacts with the TATA box-binding protein to up-regulate IGF-IR expression at the level of transcription, whereas wild-type p53 represses IGF-IR expression (44) . In addition, the IGF-I receptor gene promoter is a molecular target for the Ewing sarcoma-WT1 fusion protein (46) . In this study, we demonstrate that FOXO directly regulates IGF-IR expression. Moreover, GSK3␤ promotes IGF-IR expression through stimulating FOXO activity.
Although IGF-IR is well known as a positive regulator of a wide range of cellular processes, ranging from cellular proliferation, migration, and survival, GSK3 is a multifunctional kinase FIGURE 6. GSK3␤ positively regulates IGF-I signaling. A, HepG2 and SMMC-7721 cells were treated with or without 10 mM LiCl for 48 h, followed by treatment with or without IGF-I for 15 min. Cell lysates were subjected to Western blot analysis of IGF-IR, Akt, and ERK1/2 phosphorylation. The levels of total IGF-IR, Akt, and ERK1/2 were also detected. B, HepG2 and SMMC-7721 cells were transfected with siCtrl or siGSK3␤-1 for 48 h, followed by treatment with or without IGF-I for 15 min. Cell lysates were subjected to Western blot analysis of IGF-IR, Akt, and ERK1/2 phosphorylation. The levels of total IGF-IR, Akt, and ERK1/2 were also detected. C, HepG2 and SMMC-7721 cells were transfected with siCtrl or siGSK3␤-2 for 48 h, followed by treatment with or without IGF-I for 15 min. Cell lysates were subjected to Western blot analysis of IGF-IR, Akt, and ERK1/2 phosphorylation. The levels of total IGF-IR, Akt, and ERK1/2 were also detected.
regulating numerous signaling pathways such as NF-B, mTOR, and Wnt/␤-catenin, either positively or negatively. GSK3␤ inhibits Wnt signaling by inducing ␤-catenin phosphorylation and degradation, leading to down-regulation of protooncogenes such as c-myc and cyclin D1. Hence, GSK3␤ is recognized as a tumor suppressor. Moreover, previous studies demonstrated that GSK3␤ could inhibit mTORC1 through TSC2 phosphorylation, which is a key mediator of growth factor signaling. The inhibition of mTOR signaling by GSK3␤ requires AMP-activated protein kinase activity (47) . As shown in Fig. 8D , GSK3␤ directly activates p70 ribosomal protein S6 kinase (p70S6K), a downstream target of mTORC1 (48) . Reciprocally, p70S6K phosphorylates and then inactivates GSK3␤, indicating a negative feedback loop. Upon growth factor stimulation, GSK3␤ may be inactivated by Akt thereby releasing its inhibitory effect on mTORC1, which then takes over GSK3␤ to activate p70S6K. Therefore, GSK3␤ and mTORC1 may posi-tively regulate p70S6K under different conditions. In addition to a positive role for GSK3␤ in p70S6K activation, GSK3␤ stimulates NF-B activity thereby promoting osteosarcoma cells survival (49) . Our study highlights a positive role for GSK3␤ in IGF-IR expression and signaling. GSK3␣ has less effect than GSK3␤ on IGF-IR expression. Based on our data and previous investigations, the regulation of IGF-IR expression may involve multiple mechanisms. In resting cells, GSK3␤ and FOXO are active and positively regulate IGF-IR expression, poising IGF-IR at abundant levels ready to respond to IGF. Upon IGF stimulation, active Akt and S6K1 inhibit GSK3␤ and FOXO, allowing mTOR to be fully activated. The levels of IGF-IR, however, may decrease due to the inactivation of both GSK3 and FOXO. This is in fact the case called ligand-induced receptor down-regulation. It is known that ligand-induced IGF-IR activation is followed by proteasomal and lysosomal degradation of IGF-IR, a phenomenon of receptor desensitization (50) . Thus, Akt's phosphorylation of both FOXO and GSK3 is inhibitory (6, 53) . Therefore, under conditions in which Akt is inactive (e.g. growth factor withdrawal, serum starvation, and Akt inhibition), FOXO proteins and GSK3s are active. Consistent with the positive role of GSK3 and FOXO in IGF-IR expression, serum starvation or Akt inhibition results in increased IGF-IR expression, which can be blunted by GSK3 or FOXO inhibition. A key role of GSK3 would be boosting the abundance of IGF-IR to augment the responsiveness to its ligand when they are available. After IGF-IR is activated by its ligand, phosphorylation of Akt may in turn inactivate GSK3. Given that GSK3 may inhibit the downstream targets of Akt such as mTORC1, inactivation of GSK3 by Akt may allow the productive signal transduction. In this regard, GSK3␤ actually promotes the initiation of IGF-IR signaling.
The biological consequences of FOXO1/3/4 knockdown on hepatoma cell proliferation are very intriguing. FOXO1/3/4 depletion impairs hepatoma cell proliferation, which is in contrast to known roles of FOXO transcription factors in inducing cell cycle arrest through p27KIP1, p21, the Rb family member p130, cyclin D1, cyclin D2, cyclin G2, and GADD45 (23, 24) . Notably, the regulation of the above-mentioned genes is context-dependent. In fact, the roles of FOXO transcription factors in cancer may be complex. Previous studies also demonstrate that FOXO contributes to Akt or mTOR inhibitor resistance in cancer cells through up-regulating receptor tyrosine kinases (54). In addition, a recent study reveals that FOXO3 directly binds to DNA replication factor Cdt1 and promotes cellular proliferation (27) . This demonstrates that FOXO1/3/4 are positive regulators of hepatoma cell proliferation. Knockdown of FOXO1/3/4 blunts IGF-I-induced cellular proliferation. The regulation of IGF-IR expression may contribute, at least in part, to stimulation of hepatoma cell proliferation by FOXO. Collectively, these studies call for a revisit of FOXO transcription factors in cancer progression.
